Clinical Trials Directory

Trials / Completed

CompletedNCT07510243

Effects of Mulligan Mobilization With Movement Versus Kinesiotaping and Placebo on Knee Function and Injury -Related Outcomes in Basketball Players

Effects of Mulligan Mobilization With Movement Versus Kinesiotaping and Placebo on Knee Function and Injury -Related Outcomes in Basketball Players: A Parallel -Group Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
University Aleksander Moisiu Durres · Academic / Other
Sex
All
Age
14 Years – 22 Years
Healthy volunteers
Not accepted

Summary

This is a randomized RTC study where the KOS-ADLS score of athletes' functionality and the OSTRC score of sports overuse injuries were used as outcomes, which were measured before the start of treatment, 1 hour and 2 weeks after treatment. In this study, 3 forms of intervention were used: Mulligan, Kinesiotaping and placebo in young basketball players with knee injuries.

Detailed description

Study type: Randomized Clinical Trial RTC ,with three intervention groups. Population: young basketball players. The intervention will last 2 weeks. Outcomes: KOS-ADLS; OSTRC. Statistical analysis: Mixed ANOVA

Conditions

Interventions

TypeNameDescription
OTHERMulligan Mobilization with movement MWMParticipants received the MWM technique in a squat position with a tibial glide by a physiotherapist certified in the mulligan concept twice a week for 2 weeks, the treatment lasted 5 minutes.
OTHERKinesiotapingParticipants received the same kinesiotaping pattern regardless of injury type twice a week for 2 weeks for 5 minutes.
OTHERPlaceboParticipants received a sham intervention to mimic the treatment without therapeutic effect twice a week for 2 weeks, lasting 5 minutes.

Timeline

Start date
2025-01-06
Primary completion
2025-06-27
Completion
2026-02-27
First posted
2026-04-03
Last updated
2026-04-03

Locations

1 site across 1 country: Albania

Source: ClinicalTrials.gov record NCT07510243. Inclusion in this directory is not an endorsement.